Acquired
MacuLogix Stock
Detecting and tracking age-related macular degeneration
Sign up today and learn more about MacuLogix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About MacuLogix Stock
MacuLogix aims to detect early and track age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD.Â
Funding History
| July 2012 | $2.9M |
|---|---|
| March 2013 | $3.6M |
| June 2014 | $3.6M |
| October 2015 | $5.0M |
| July 2018 | $10.0M |
| March 2019 | $38.7M |
Management
Co-founder and Chief Scientific Officer
Gregory R. Jackson
CEO
Bill McPhee
Press
prnewswire - Jul, 26 2022
LumiThera, Inc. Announces Purchase of MacuLogix Assetsnewswire - Jan, 18 2020
MacuLogix Introduces the AdaptDx Pro, Guided by Theianewswire - Nov, 15 2019
MacuLogix Hires Christine W. Silverberg as Director of National Accountsnewswire - Oct, 23 2019
'Practical Strategies for Preventing Blindness Caused by AMD' Offers Clear Framework on How to Manage AMD in Optometric Practicefinsmes - Sep, 29 2015
MacuLogix Raises $3.6M in Series A FundingEquityZen Recognized As:
